Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
NCT07551050 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2026-04-24
Summary
A real-world, multicenter, prospective study to evaluate the patient-reported outcome in Chinese patients who received sacituzumab govitecan or chemotherapy of the physician's choice for metastatic breast cancer progressing on first-line treatment
Conditions
- TNBC - Triple-Negative Breast Cancer
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-15
- Primary Completion
- 2029-04-15
- Completion
- 2029-06-15
Countries
- China
Study Locations
More Related Trials
-
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
NCT06101082 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT04734262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
NCT07271992 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients
NCT04537286 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
NCT06413615 ·Status: RECRUITING ·Phase: PHASE2
-
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
NCT04766515 ·Status: RECRUITING
-
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases
NCT05129202 ·Status: COMPLETED
-
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
NCT02362230 ·Status: TERMINATED ·Phase: PHASE2
-
Trop-2 Targeted PET Probes in Advanced TNBC
NCT07046455 ·Status: RECRUITING ·Phase: NA
-
High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor
NCT05755009 ·Status: UNKNOWN ·Phase: NA
-
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
NCT07565532 ·Status: RECRUITING
-
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
NCT07401537 ·Status: RECRUITING ·Phase: PHASE2
-
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
NCT05300958 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
NCT03944499 ·Status: COMPLETED ·Phase: PHASE1
-
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
NCT03668366 ·Status: COMPLETED ·Phase: PHASE2
-
SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma
NCT04351282 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer
NCT03151447 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005 ·Status: RECRUITING ·Phase: PHASE2
-
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
NCT05904015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer
NCT02063893 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
NCT05068141 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
NCT04262804 ·Status: UNKNOWN ·Phase: PHASE2
-
Mix Vaccine for Metastatic Sarcoma Patients
NCT03357315 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
NCT07258147 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2